News

Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...
Fierce Pharma22h
Fierce Pharma Asia—Moderna's scrapped Japanese plant; Rexulti's adcomm setback; Pfizer's option in 3SBio
Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...